Clik here to view.
Celgene acquires Delinia, beats on Q4 earnings
Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results. The Summit, N.J.-based company posted...
View ArticleClik here to view.
Novo Nordisk puts $145m into U.K. research center
(Reuters) – Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit. The Danish company said on...
View ArticleClik here to view.
Researchers develop immune cells that infiltrate tumors
Researchers from the Okayama University have developed a group of immune cells that can infiltrate tumors and deliver viral vectors, destroying them from the inside out. The team’s work was published...
View ArticleClik here to view.
Merck becomes latest to offer insight into drug pricing practices
Last week, Merck (NYSE:MRK) released figures about its U.S. pricing practices, joining a growing list of companies that are revealing their pricing strategies amid criticism of the industry’s price...
View ArticleClik here to view.
Insulin makers face class-action lawsuit over price collusion
A class-action lawsuit filed in the U.S. District Court of Massachusetts alleges that insulin makers Sanofi (NYSE:SNY), Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) conspired to raise their list...
View ArticleClik here to view.
Mylan hit with antitrust lawsuit over EpiPen device
Mylan (NSDQ:MYL) said on Monday that it is undergoing an antitrust probe by the Federal Trade Commission into the company’s commercial practices regarding its EpiPen device. The Canonsburg, Pa.-based...
View ArticleClik here to view.
Pfizer misses on Q4 earnings
Shares in Pfizer (NYSE:PFE) remained steady today after the pharmaceutical company missed expectations on Wall Street with its 4th quarter results. The U.S. pharma giant posted profits of $775 million,...
View ArticleClik here to view.
Eli Lilly posts mixed Q4 earnings
Shares in Eli Lilly (NYSE:LLY) rose today after the drug manufacturer missed earnings expectations, but beat revenue estimates on Wall Street with its 4th quarter results. The Indianapolis-based...
View ArticleClik here to view.
Trump presses pharma execs on pricing, U.S. production
Executives from pharmaceutical companies including Johnson & Johnson (NYSE:JNJ), Amgen (NSDQ:AMGN), Merck (NYSE:MRK) and Eli Lilly (NYSE:LLY) met with President Donald Trump today to discuss issues...
View ArticleClik here to view.
MediWound touts Phase II study
MediWound (NSDQ:MDWD) touted data from a phase II trial of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. The data includes a follow-up period of 6...
View ArticleClik here to view.
Glide raises $4m for phase I trial of solid-dose teriparatide
Glide Technologies said today that it raised £3.2 million, or $4.0 million USD, in a round of financing. A number of existing investors contributed to the round, according to the Oxford-based company....
View ArticleClik here to view.
Cohero raises $13.3m for connected inhaler tech
Cohero Health said today that it raised more than $13.3 million, according to regulatory filings, in equity and Series A preferred stock. The company sold nearly all of its total offering amount of...
View ArticleClik here to view.
Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri...
View ArticleClik here to view.
Amgen tops Q4 earnings, touts Repatha cardiovascular outcomes
Shares in Amgen (NSDQ:AMGN) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results and touted data from a trial for its cholesterol drug, Repatha. The...
View ArticleClik here to view.
Sens. Sanders, Cruz talk drug pricing, Obamacare in town hall debate
Sens. Bernie Sanders (I-Vermont) and Ted Cruz (R-Texas) met last night to debate the future of Obamacare in a town-hall debate. The 2 senators are opposed on how to provide health care coverage to...
View ArticleClik here to view.
Allergan ticks up on Q4, 2016 beats
Allergan (NYSE: AGN) shares ticked up today after the company reported 4th-quarter and full-year earnings – and a 2017 sales forecast – that beat expectations on Wall Street. The drugmaker narrowed its...
View ArticleClik here to view.
Eli Lilly wins label expansion for Trulicity injection with basal insulin
Eli Lilly (NYSE:LLY) said today that the FDA approved label changes for its once-weekly Trulicity injection. The new label was updated to include use in combination with basal insulin for adults with...
View ArticleClik here to view.
Acorda’s inhaled Parkinson’s drug meets primary endpoint in Phase III trial
Acorda Therapeutics (NSDQ:ACOR) said today that the phase III clinical trial evaluating its inhaled formulation of Parkinson’s drug levodopa met its primary endpoint. The drug was studied as a therapy...
View ArticleClik here to view.
Researchers develop bioink for 3D-printed pills
Researchers at the University of California Los Angeles have developed a viable bioink made out of hyaluronic acid for 3D-printed pills. In this study, researchers used an inket technique to 3D print...
View ArticleClik here to view.
Marathon hikes MD drug price 70x to $89k a year
After winning FDA approval for its muscular dystrophy drug last week, Marathon Pharmaceuticals set the drug’s list price at $89,000 a year – 50 to 70 times greater than what most U.S. patients have...
View Article